immunoprecise antibodies is a highly specialized customer focused life sciences company that provides custom antibody development and immunology services from its headquarters in beautiful victoria, bc, canada. our dedication to advancing antibody development has resulted in cutting-edge immunological innovations such as single-step cloning, rapid prime immunization strategies, and recombinant monoclonal technology. we pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving thorough and professional service. we customize your project to generate antibodies that meet your specific needs. over our 20+ year history, we have gained the trust of a diverse group of customers that include research agencies, universities, biotechnology and pharmaceutical companies of all sizes from around the globe. immunoprecise is pleased to announce its newest line of services, immunoprotect™. with immunoprotect™, the dna sequence of your mab is determined and ca
Company profile
Ticker
IPA
Exchange
Website
CEO
Jennifer Bath
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IPA stock data
Latest filings (excl ownership)
6-K
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
20 Mar 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
7 Mar 24
6-K
Current report (foreign)
23 Feb 24
424B5
Prospectus supplement for primary offering
23 Feb 24
6-K/A
Current report (foreign) (amended)
15 Feb 24
6-K
Material Change Report
14 Dec 23
6-K
Current report (foreign)
14 Dec 23
6-K
Immunoprecise Antibodies LTD. 6-K
14 Dec 23
Transcripts
IPA
Earnings call transcript
2024 Q3
14 Mar 24
IPA
Earnings call transcript
2024 Q2
14 Dec 23
IPA
Earnings call transcript
2024 Q1
14 Sep 23
IPA
Earnings call transcript
2023 Q4
7 Jul 23
IPA
Earnings call transcript
2023 Q3
16 Mar 23
IPA
Earnings call transcript
2023 Q2
15 Dec 22
IPA
Earnings call transcript
2023 Q1
14 Sep 22
IPA
Earnings call transcript
2022 Q3
16 Mar 22
IPA
Earnings call transcript
2022 Q2
14 Dec 21
IPA
Earnings call transcript
2022 Q1
10 Sep 21
Financial summary
Quarter (USD) | Apr 23 | Apr 22 | Apr 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Apr 23 | Apr 22 | Apr 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
5.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 1.03 bn |
Total shares | 1.43 mm |
Total puts | 24.10 k |
Total calls | 351.80 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Ingalls & Snyder | 1.06 mm | $3.14 mm |
BMO Bank of Montreal | 208.11 k | $668.03 mm |
CIBC World Markets | 42.43 k | $126.00 k |
Citadel Advisors | 34.78 k | $102.96 mm |
Gradient Capital Advisors | 26.81 k | $79.35 mm |
Dimensional Fund Advisors | 26.74 k | $79.14 mm |
Geode Capital Management | 17.48 k | $51.75 mm |
Tower Research Capital | 7.57 k | $22.40 mm |
RY Royal Bank Of Canada | 3.15 k | $9.00 mm |
Group One Trading | 1.58 k | $4.68 mm |
News
EXCLUSIVE: Immunoprecise Antibodies and InterSystems Integrate Vector Search With LENSai For AI-Driven Healthcare Applications
28 Mar 24
Benchmark Reiterates Speculative Buy on ImmunoPrecise Antibodies, Maintains $5 Price Target
15 Mar 24
HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target
15 Mar 24
ImmunoPrecise Antibodies Q3 2024 GAAP EPS $(0.08) Beats $(0.10) Estimate, Sales $4.555M Miss $6.068M Estimate
14 Mar 24
Earnings Scheduled For March 14, 2024
14 Mar 24
Press releases
InterSystems and IPA's Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
28 Mar 24
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
14 Mar 24
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology
8 Mar 24
IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
7 Mar 24
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
4 Mar 24